IP Library Granted Patent US 10,308,712
Granted Patent B2
US 10,308,712 · App. 14/774,582 · Granted Jun 4, 2019

Antibodies that bind human cannabinoid 1 (CB1) receptor

Inventors: Anke Kretz-Rommel (San Diego, CA); Lei Shi (Shanghai, CN); Roger Ferrini (Solana Beach, CA); Teddy Yang (Shanghai, CN); Fei Xu (Palm Beach Gardens, FL); Brian Campion (La Jolla, CA)
Assignee: BIRD ROCK BIO, INC.
C07K16/28A61K47/6849A61K2039/505C07K2317/24C07K2317/33C07K2317/52C07K2317/526C07K2317/53C07K2317/55C07K2317/56C07K2317/565C07K2317/71C07K2317/732C07K2317/734C07K2317/76C07K2317/77C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,712
App. No.
14/774,582
Granted
Jun 4, 2019
Kind
B2
Abstract

The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.

Claims (25)

1. An isolated antibody or antigen binding fragment thereof that binds to cannabinoid receptor 1 (CB1), wherein the antibody or antigen binding fragment comprises:

a heavy chain comprising a CDR1 amino acid sequence of SEQ ID NO: 352, a CDR2 amino acid sequence of SEQ ID NO: 353, and a CDR3 amino acid sequence of SEQ ID NO: 354; and

a light chain comprising a CDR1 amino acid sequence of SEQ ID NO: 355, a CDR2 amino acid sequence of SEQ ID NO: 356, and a CDR3 amino acid sequence of SEQ ID NO: 357.

2. The isolated antibody or antigen binding fragment of claim 1 , comprising:

a heavy chain variable region comprising SEQ ID NO: 2; and

a light chain variable region comprising SEQ ID NO: 6.

3. The isolated antibody or antigen binding fragment of claim 1 , comprising:

a heavy chain variable region comprising SEQ ID NO: 339, and

a light chain variable region comprising SEQ ID NO:337.

4. The isolated antibody or antigen binding fragment of claim 1 , comprising:

a heavy chain variable region comprising SEQ ID NO: 340, and

a light chain variable region comprising SEQ ID NO:337.

5. The isolated antibody or antigen binding fragment of claim 1 , comprising:

a heavy chain variable region comprising SEQ ID NO: 341, and

a light chain variable region comprising SEQ ID NO:337.

6. The isolated antibody or antigen binding fragment of claim 1 , comprising:

a heavy chain amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 436-441, and

a light chain amino acid sequence comprising SEQ ID NO:338.

7. The isolated antibody or antigen binding fragment of claim 1 , comprising:

a heavy chain amino acid sequence comprising SEQ ID NO: 437, and

a light chain amino acid sequence comprising SEQ ID NO:338.

8. The isolated antibody or antigen binding fragment of claim 1 , wherein the antibody is conjugated to a therapeutic agent, a cytotoxic agent, an immunoadhesion molecule, or an imaging agent.

9. The isolated antibody or antigen binding fragment of claim 2 , further comprising:

a heavy chain constant region comprising SEQ ID NO: 4, and

a light chain constant region comprising SEQ ID NO: 8.

Assignments (5)
MERGER AND CHANGE OF NAME Recorded Aug 12, 2024
From: AQUILA MERGER SUB, INC.; BIRD ROCK BIO, INC.
To: BIRD ROCK BIO SUB, INC.
Reel/Frame 068250/0218 →
CHANGE OF NAME Recorded Aug 15, 2016
From: RUIYI, INC.
To: BIRD ROCK BIO, INC.
Reel/Frame 039684/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2015
From: RUIYI BIOPHARMACEUTICS TECHNOLOGY (SHANGHAI) CO., LTD.
To: RUIYI, INC.
Reel/Frame 036624/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2015
From: KRETZ-ROMMEL, ANKE; FERRINI, ROGER; XU, FEI; CAMPION, BRIAN
To: RUIYI, INC.
Reel/Frame 036610/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2015
From: SHI, LEI; YANG, TEDDY
To: RUIYI BIOPHARMACEUTICS TECHNOLOGY (SHANGHAI) CO., LTD.
Reel/Frame 036610/0198 →
Priority Claims (2)
WO PCT/CN2014/074199 · Mar 27, 2014 · international
WO PCT/CN2014/081797 · Jul 8, 2014 · international
Continuity (1)
Related Publication 20170210797A1 · Jul 27, 2017